SDGR

Schrodinger is two businesses bolted together: a genuinely valuable physics-based computational platform that's licensed to pharma/industrial customers, and a proprietary drug-discovery moonshot. The software/collaboration engine is working — FY2025 revenue grew 23.3% to $256M with a 55.7% gross margin, and the loss narrowed sharply from -$187M to -$103M. Critically, operating cash flow turned positive at $13.9M and cash actually rose 56.5% to $231M, so this is not a company at the edge of a financing cliff. Against ~$1.28B market cap, that's a P/S of 5.0 — a full but not absurd multiple for a high-margin, double-digit grower.

The filing, however, marks a strategic retreat that reframes the story. Management is 'phasing out independent clinical development': beyond completing the Phase 1 trials of SGR-1505 and SGR-3515, they 'do not intend to initiate additional clinical trials or advance other proprietary preclinical programs independently,' and will instead seek strategic partners. This follows a May 2025 restructuring and the August 2025 discontinuation of SGR-2921 after two patient deaths were considered drug-contributed. The cost discipline is welcome and explains the narrower loss and lower R&D (-14.2%), but it is also an admission that the self-funded drug pipeline — the high-upside optionality embedded in the stock — isn't viable on the balance sheet they have. The MD&A is candid that the 2023 profit was a one-off Nimbus/Structure gain, not operating strength, and that equity-stake gains 'will fluctuate significantly.'